Regeneron assumes no responsibility for the User Content on the page, nor for any error, defamation, libel, slander, omission falsehood, obscenity, pornography, profanity, danger or inaccuracy contained in any User Content.

You understand and agree that User Content will be treated as non-confidential and non-proprietary and you are giving us and our affiliates, a royalty-free, irrevocable, perpetual, non-exclusive and fully sublicensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such User Content in whole or in part, on a worldwide basis, and to incorporate them in other works, in any form, media, technology, or products now known or later developed, including for promotional or marketing purposes; and you further represent, warrant, and covenant that you have and will continue to have the legal right to grant these rights.

Please read Facebook's Statements of Rights and Responsibilities for more information.

Adverse Events
This page is not the best place to discuss safety issues or side effects associated with our products or other company’s products. If you, or someone you know, may have possibly experienced a side effect while taking a Regeneron product please contact our Medical Information Department at 1-855-REGEN-4-U (1-855-734-3648) for further information. You can also report any adverse event directly to your healthcare provider or to the U.S. Food and Drug Administration (FDA) by calling 1-800-FDA-1088 or visiting http://www.fda.gov/Safety/MedWatch.">
OClawVPS.com
Regeneron
Edit

Regeneron

https://www.regeneron.com/
Last activity: 03.04.2026
Active
Categories: BiotechGeneticsImmunologyOncologyPharmaceuticals
Please visit www.Regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media.

Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts. Any questions about job listings can be directed to candidatesupport@regeneron.com.

Regeneron is a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including ophthalmology, asthma, atopic dermatitis, pain, cancer and infectious diseases. In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.

Milestones
1988: Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College. Learn more about our history and milestones here:
https://www.regeneron.com/history

Commenting Guidelines
Thank you for visiting our page. This is a place where we hope you will engage with and learn more about our company and take part in open dialogue that respects other members. We want to hear from you and we’ll respond to your comments and questions as soon as possible.

We respect your right to voice your opinions, but we reserve the right to remove any comments that are considered inappropriate, off-topic, or abusive.
Please don’t use this page to solicit for third-party sites or products.

Comments that are factually inaccurate or misleading, violate another's copyright or intellectual property, use profanity or are defamatory will be deleted.

The content you read here may contain information related to health, medical and fitness conditions and treatment. It is for informational purposes only and not a substitute for professional medical advice, diagnosis, or treatment. Please always consult your doctor.

All comments, visuals, videos and other type of material posted by fans on this site ("User Content") do not necessarily reflect the opinions or ideals of Regeneron, its employees or affiliates.
Regeneron assumes no responsibility for the User Content on the page, nor for any error, defamation, libel, slander, omission falsehood, obscenity, pornography, profanity, danger or inaccuracy contained in any User Content.

You understand and agree that User Content will be treated as non-confidential and non-proprietary and you are giving us and our affiliates, a royalty-free, irrevocable, perpetual, non-exclusive and fully sublicensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such User Content in whole or in part, on a worldwide basis, and to incorporate them in other works, in any form, media, technology, or products now known or later developed, including for promotional or marketing purposes; and you further represent, warrant, and covenant that you have and will continue to have the legal right to grant these rights.

Please read Facebook's Statements of Rights and Responsibilities for more information.

Adverse Events
This page is not the best place to discuss safety issues or side effects associated with our products or other company’s products. If you, or someone you know, may have possibly experienced a side effect while taking a Regeneron product please contact our Medical Information Department at 1-855-REGEN-4-U (1-855-734-3648) for further information. You can also report any adverse event directly to your healthcare provider or to the U.S. Food and Drug Administration (FDA) by calling 1-800-FDA-1088 or visiting http://www.fda.gov/Safety/MedWatch.
Likes
14.8K
Followers
305.37K
Website visits
153K /mo.
Mentions
373
Location: United States
Employees: 10001+
Phone: +1 914-847-7000
Founded date: 1988

Investors 2

Mentions in press and media 373

DateTitleDescription
03.04.2026TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health SolutionsRegeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and prot...
27.03.2026AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failedBritain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former s...
20.03.2026How CNBC Cures is bringing rare disease stories to a national audience“Squawk Box” co-host Becky Quick launched CNBC Cures in January, the network’s initiative to raise awareness for rare diseases. Since its launch, CNBC has rolled out a weekly CNBC Cures newsletter, a podcast, a live event, and has featured ...
20.02.2026Curt Smith: Fighting blood cancer is easier with a group effort-
18.02.2026Avantos Raises $25M in Series A FundingAvantos, a NYC-based provider of an artificial intelligence (“AI”)-native operating system, raised $25M in Series A funding. The round was led by Bessemer Venture Partners with participation from new strategic investors, including The Guard...
18.02.2026Armistice Capital Among Funds With Exposure to Regeneron as Biopharma Focus Shifts Back to Late-Stage Executionx Please enable JavaScript Video Player is loading.Play Video Play Unmute 1xPlayback Rate 2x1.5x1x, selected0.5x Captions captions off, selectedAmerican English CaptionsWatch on Open.Video ShareFullscreen Now Playing Up NextGovernmental Fun...
08.02.2026Almost 4,000 girls to attend 12th annual I Wish Festival at the RDSAlmost 4,000 female teenage students from across the island are expected to attend the 12th annual I Wish Festival at the RDS, Dublin. The event is focused on promoting STEM subjects, science, technology, engineering, and mathematics to gir...
24.01.2026BrightInsight Secures $13M: AI Fuels Medication Adherence RevolutionBrightInsight secured $13 million in new funding. This capital accelerates AI-driven medication adherence solutions. It will scale global patient support programs. Top investors, including Mayo Clinic, backed the digital health leader. The ...
22.01.2026Think Bioscience Secures $55M Series A for 'Undruggable' Target TherapiesThink Bioscience, a Boulder, CO-based drug discovery innovator, closed an oversubscribed $55 million Series A funding round. This substantial investment accelerates R&D and operational expansion. The firm pioneers small molecule therape...
21.01.2026BrightInsight: $13 Million Closed To Expand AI-Enabled Medication Adherence PlatformBrightInsight has raised $13 million in funding to accelerate the development of its AI-enabled medication persistence and adherence solutions and scale patient support programs globally. The San Jose-based digital health company said the r...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In